Marché mondial des ulcères gastriques – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché

Les ulcères gastroduodénaux, également appelés ulcères gastriques, sont un type d'ulcère gastrique qui provoque des douleurs et une gêne abdominales. Les ulcères gastroduodénaux sont divisés en deux types : les ulcères gastriques et les ulcères duodénaux. Les ulcères gastriques sont une manifestation typique de la paroi interne de l'estomac. La perte de la couche de mucus qui protège l'estomac des fluides digestifs provoque ces ulcères. Les éructations, les nausées, les vomissements, la perte d'appétit et d'autres symptômes des ulcères gastriques sont courants. Le type d'ulcère gastrique détermine le traitement, qui comprend généralement des inhibiteurs de la pompe à protons et des antibiotiques.

Français Data Bridge Market Research analyse que le marché des ulcères gastriques était évalué à 3,98 milliards USD en 2021 et devrait atteindre 5,57 milliards USD d'ici 2029, enregistrant un TCAC de 4,30 % au cours de la période de prévision de 2022 à 2029. En plus des informations sur le marché telles que la valeur du marché, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe de Data Bridge Market Research comprend également une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Portée du rapport et segmentation du marché

Market Definition

Stomach ulcers are open sores caused by damage to the stomach lining. Also known as gastric ulcers, stomach ulcers are ulcers that affect the stomach. Typically, treatment involves destroying the H. pylori bacterium if it is present, lowering or eliminating the use of non-steroidal anti-inflammatory drugs (NSAIDs) if possible, and aiding the healing of your ulcer using medication. If the ulcer was induced by NSAIDs, treatment with a proton pump inhibitor (PPI). Alternatives to non-steroidal anti-inflammatory drugs (NSAIDs) may be offered, such as paracetamol. If an H. pylori infection caused the ulcer, antibiotics may be used to treat it. This destroys the germs, preventing the ulcer from returning.

Gastric Ulcers Market Dynamics

Drivers

• Increasing prevalence of gastric ulcers

The rising prevalence of gastric ulcers across the globe is estimated to enhance the market's growth. A stomach ulcer develops when gastric acid eats away at your stomach's protective lining. The acid causes open sores on the stomach that can bleed and cause pain. Gastric ulcer disease manifests itself in a variety of ways, one of which is stomach ulcers. Drugs that reduce gastric ulcer secretion, such as PPIs and H2 receptor antagonists, as well as acid neutralization agents, such as antacids and antibiotics against H. pylori infection, are used to treat peptic ulcers. However, for effective treatment, these medicines are frequently taken in combination.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of gastric ulcers market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the gastric ulcers market. Additionally, the sedentary lifestyle of people such as high alcohol consumption and addiction of smoking will result in the expansion of gastric ulcers market. Rising level of disposable income and surging geriatric population are the major factors anticipated to flourish the market’s growth rate during the forecast period of 2022-2029.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the gastric ulcers market growth. In the peptic ulcer market, companies are pursuing long-term tactics to acquire a competitive advantage, such as new product launches, collaboration partnerships, and product upgrades. RedHill Biopharma announced the commercial introduction of Talicia, a pill to treat H.pylori infection in patients, in the United States in March 2020. The major pharmaceutical company's declaration is anticipated to boost its market position in the future years. 

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of gastric ulcers during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the gastric ulcers market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This gastric ulcers market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the gastric ulcers market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

In Western countries, stomach ulcers are fairly prevalent. There are around 4 million instances every year in the United States. According to some estimates, one out of every ten people will experience one at some point in their lives. This is due to the fact that many of the factors that contribute to stomach ulcers are ubiquitous in modern society.

Gastric ulcers market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Global Gastric Ulcers Market Scope

The gastric ulcers market is segmented on the basis of drug class, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Proton Pump Inhibitors (PPI)
• H2 Antagonists
• Antacids
• Antibiotics
• Cytoprotective Agents
• Others

Diagnosis

• Stool Test
• Endoscopy
• Imaging Tests
• CT scan
• X-ray
• Others
• Blood Tests
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Gastric Ulcers Market Regional Analysis/Insights

The gastric ulcers market is analysed and market size insights and trends are provided by country, drug class, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the gastric ulcers market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the gastric ulcers market because of the rising prevalence of gastric ulcers and technological advancement in the treatment in this region. Additionally, rising healthcare expenditure and the presence of major key players will further propel the market’s growth rate.

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing geriatric population and surging level of disposable income in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.   

Analyse du paysage concurrentiel et des parts de marché des ulcères gastriques

Le paysage concurrentiel du marché des ulcères gastriques fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché des ulcères gastriques.

Certains des principaux acteurs opérant sur le marché des ulcères gastriques sont :

• F. Hoffmann-La Roche SA (Suisse)
• Mylan NV (États-Unis)
• Teva Pharmaceutical Industries Ltd. (Irlande)
• Sanofi (France)
• Pfizer Inc. (États-Unis)
• GlaxoSmithKline plc (Royaume-Uni)
• Novartis SA (Suisse)
• Merck & Co., Inc. (États-Unis)
• Allergan (Irlande)
• AstraZeneca (Royaume-Uni)
• Johnson & Johnson Private Limited (États-Unis)
• Hikma Pharmaceuticals PLC (Royaume-Uni)
• Société Bristol-Myers Squibb (États-Unis)
• Bayer AG (Allemagne)
• Boehringer Ingelheim International GmbH. (Allemagne)
• Dr. Reddy's Laboratories Ltd. (Inde)
• Gilead Sciences, Inc. (États-Unis)
• Amgen Inc. (États-Unis)
• Eli Lilly and Company (États-Unis)
• AbbVie Inc. (États-Unis)
• Lupin (Inde)
• Allergan (Irlande)

SKU-53470